Cerivastatin sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for cerivastatin sodium and what is the scope of patent protection?

Cerivastatin sodium is the generic ingredient in one branded drug marketed by Bayer Pharms and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for cerivastatin sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	37
DailyMed Link:	cerivastatin sodium at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for cerivastatin sodium

C10AA	HMG CoA reductase inhibitors
C10A	LIPID MODIFYING AGENTS, PLAIN
C10	LIPID MODIFYING AGENTS
C	Cardiovascular system

US Patents and Regulatory Information for cerivastatin sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-003	Jun 26, 1997		DISCN	No	No
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-005	May 24, 1999		DISCN	No	No
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-002	Jun 26, 1997		DISCN	No	No

Expired US Patents for cerivastatin sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-005	May 24, 1999
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-002	Jun 26, 1997
Bayer Pharms	BAYCOL	cerivastatin sodium	TABLET;ORAL	020740-004	Jun 26, 1997

Cerivastatin Sodium Market Dynamics, Withdrawal, Litigation, and Financial Trajectory

Last updated: September 7, 2026

Cerivastatin sodium has no current commercial market. Bayer AG withdrew Baycol in the United States on August 8, 2001, after reports linked the drug to severe rhabdomyolysis and fatal kidney failure. The withdrawal ended new-product revenue, eliminated future generic-launch value, and shifted the drug’s financial profile from commercial growth to litigation, recall, and regulatory costs. Cerivastatin’s market position was also weakened by competition from atorvastatin, simvastatin, pravastatin, and other statins with broader clinical use and more established safety records.

What was cerivastatin sodium and how was it commercialized?

Cerivastatin sodium was a synthetic HMG-CoA reductase inhibitor developed to reduce low-density lipoprotein cholesterol. Bayer marketed it under the names Baycol in the United States and Canada and Lipobay in several other markets. The drug was administered orally in low-microgram doses, including 0.3 mg and 0.4 mg strengths.

The product received FDA approval in 1997. It entered a statin market dominated by established products from Merck, Pfizer, Bristol-Myers Squibb, AstraZeneca, and other manufacturers. Cerivastatin was positioned as a potent low-dose statin, but its commercial expansion depended heavily on dose selection, coadministration risks, and physician confidence in safety.

Key product facts

Attribute	Cerivastatin sodium
Active ingredient	Cerivastatin
Drug class	HMG-CoA reductase inhibitor
U.S. brand	Baycol
International brand	Lipobay
Developer and principal manufacturer	Bayer AG
FDA approval	1997
Primary indication	Hypercholesterolemia and mixed dyslipidemia
Dosage form	Oral tablets
U.S. withdrawal	August 8, 2001
Current U.S. commercial status	Discontinued
Biosimilar exposure	None; cerivastatin is a small molecule
Current generic-launch opportunity	None of practical commercial significance

The clinical risk was concentrated in severe muscle toxicity, particularly rhabdomyolysis. Risk increased when cerivastatin was used with gemfibrozil, a fibrate used to treat lipid disorders. The FDA identified a disproportionate number of serious adverse-event reports in patients receiving the combination, although serious events also occurred with cerivastatin monotherapy and other risk factors (U.S. Food and Drug Administration [FDA], 2001).

When did cerivastatin lose market exclusivity?

Cerivastatin lost commercial exclusivity when Bayer withdrew the product, not when a generic competitor entered the market. The withdrawal occurred before patent expiry could produce a conventional generic-entry cycle in the United States.

Publicly available FDA and Bayer materials do not establish a commercially relevant post-withdrawal patent period for cerivastatin. The product’s market value collapsed because regulators and Bayer removed it from distribution. Any remaining composition, formulation, or use patents became economically secondary to the product’s safety profile and discontinued regulatory status.

Patent and exclusivity position

Issue	Market impact
Core drug patent protection	Could have supported exclusivity before withdrawal
FDA regulatory exclusivity	No longer commercially relevant after withdrawal
Orange Book listing	No current marketed U.S. product
Paragraph IV challenges	No material modern challenge associated with a commercial U.S. launch
Formulation patents	Did not preserve commercial value after withdrawal
Method-of-use patents	Could not support ongoing sales without an approved product
Generic entry	No meaningful launch followed withdrawal
Biosimilar risk	Not applicable to this small-molecule drug

Cerivastatin should therefore be analyzed as a withdrawn product rather than as a mature branded medicine facing ordinary loss of exclusivity.

How did cerivastatin sales develop before withdrawal?

Cerivastatin generated meaningful revenue during its short commercial life. Bayer’s annual reports identify Baycol and Lipobay as important products before the withdrawal, although reported sales varied by year, currency, product grouping, and geographic market.

Industry and company reporting commonly place peak annual cerivastatin sales in the several-hundred-million-dollar range, with some contemporary estimates approaching or exceeding $1 billion on a global basis when Baycol and Lipobay sales are aggregated. The exact figure depends on whether the calculation uses reported net sales, pre-withdrawal annualized sales, or broader forecasts.

Commercial trajectory

Period	Commercial position	Financial effect
1997-1998	U.S. and international launch	Initial commercialization costs and formulary development
1999-2000	Rapid prescription growth	Rising branded-statins revenue
Early 2001	Safety concerns and label restrictions	Slower growth and declining physician confidence
August 2001	Global withdrawal	Immediate loss of product revenue
2001-2005	Recall and litigation period	Charges, legal reserves, defense costs, and settlement payments
After 2005	Residual legal and reputational exposure	No meaningful operating revenue

The product’s growth reflected the expansion of the cholesterol-treatment market and the ability of statins to reduce cardiovascular risk. The growth case was damaged by competition from atorvastatin and simvastatin, which had larger clinical and commercial franchises. Cerivastatin also lacked the long-established prescribing base of pravastatin and lovastatin.

Why was cerivastatin withdrawn?

Bayer withdrew cerivastatin after mounting reports of rhabdomyolysis and deaths. Rhabdomyolysis can produce acute kidney injury and death when skeletal muscle breakdown releases intracellular contents into the bloodstream.

The combination with gemfibrozil was a major safety concern. Gemfibrozil inhibited the metabolism and clearance of cerivastatin, increasing systemic exposure. Bayer had reduced the recommended dose for patients receiving the combination, but adverse-event reports continued.

In August 2001, Bayer announced the worldwide withdrawal of Baycol and Lipobay. The FDA supported the withdrawal and advised patients and physicians to stop using the product and switch to alternative lipid-lowering treatment (FDA, 2001).

FDA regulatory status

Cerivastatin is not an active U.S. commercial product. Its regulatory history is defined by withdrawal rather than by a pending approval, supplemental indication, or postmarketing expansion.

The FDA’s regulatory action had four direct financial effects:

1. It stopped new prescriptions and product shipments.
2. It required inventory withdrawal and product recall activity.
3. It eliminated the future value of planned indications and market expansion.
4. It increased exposure to product-liability claims and regulatory scrutiny.

The withdrawal also changed the competitive market. Physicians moved patients to other statins, particularly atorvastatin, simvastatin, pravastatin, and rosuvastatin after its later launch.

What litigation affected cerivastatin and Bayer?

Cerivastatin generated extensive product-liability litigation in the United States. Plaintiffs alleged that Baycol caused rhabdomyolysis, kidney injury, dialysis, and death. Claims also examined Bayer’s warnings, dose restrictions, pharmacokinetic interactions, and communications concerning the risks of combining cerivastatin with gemfibrozil.

Bayer created provisions and incurred charges related to product-liability litigation. Public reporting during the mid-2000s placed Bayer’s Baycol-related litigation and settlement exposure in the billion-dollar range, although totals varied as claims were dismissed, settled, tried, or remained unresolved. Bayer’s annual reports provide the most reliable basis for separating recognized charges, cash payments, and contingent liabilities (Bayer AG, 2001-2005).

Litigation status and settlement profile

The principal litigation issues were:

• Whether Bayer adequately warned about rhabdomyolysis.
• Whether the gemfibrozil interaction was sufficiently communicated.
• Whether Bayer delayed withdrawal after receiving adverse-event information.
• Whether individual injuries were medically attributable to cerivastatin.
• Whether patients used doses or drug combinations outside labeled recommendations.

The legal exposure was materially larger than the product’s remaining revenue opportunity after withdrawal. This asymmetry is important for financial analysis: a product with hundreds of millions of dollars in annual sales can create multiyear liabilities several times greater than its final-year revenue when a serious safety signal affects a large patient population.

What happened to cerivastatin’s revenue after withdrawal?

Revenue fell sharply after August 2001. Product sales ceased in the United States and were progressively eliminated in other markets. There was no meaningful recovery through relaunch, reformulation, licensing, or acquisition.

The financial trajectory had four stages:

1. Pre-withdrawal growth

Bayer invested in sales, marketing, manufacturing, regulatory support, and clinical positioning. The drug generated recurring prescription revenue and contributed to Bayer’s pharmaceutical portfolio.

2. Abrupt revenue destruction

The global withdrawal removed cerivastatin from the branded statin market. Remaining inventory was subject to returns, destruction, or controlled disposition. Forecast revenue, brand equity, and future indication value were written off.

3. Liability and remediation period

Bayer incurred legal defense costs, settlement payments, recall expenses, regulatory costs, and insurance-related effects. The company also faced reputational damage within its pharmaceutical business.

4. Residual exposure

After the main claims were resolved or settled, the product retained no material operating revenue. Any remaining financial effect came from residual litigation, insurance recovery, record retention, or corporate reporting obligations.

How did cerivastatin compare with competing statins?

Cerivastatin’s commercial failure was caused by safety risk, but competitive pressure had already limited its strategic position.

Drug	Principal company during key commercial period	Market position	Relative outcome
Cerivastatin	Bayer	Potent low-dose statin	Withdrawn globally in 2001
Atorvastatin	Pfizer	Large, high-growth branded statin franchise	Became a leading global statin
Simvastatin	Merck	Established statin with broad use	Benefited from physician switching
Pravastatin	Bristol-Myers Squibb	Long-established safety-oriented option	Retained substantial use
Fluvastatin	Novartis	Smaller statin franchise	Continued in selected markets
Rosuvastatin	AstraZeneca	Later high-potency entrant	Expanded the high-intensity statin segment

Cerivastatin had limited ability to compete on price because its withdrawal removed the product from the market. It also had no durable advantage in delivery technology, formulation differentiation, or patient convenience. The drug was an oral immediate-release product in a therapeutic class with several substitutes.

What generic entry risks existed for cerivastatin?

There was no conventional Paragraph IV generic-entry event after withdrawal. Generic manufacturers could theoretically have pursued an abbreviated new drug application if a reference product remained available and the regulatory pathway were commercially viable. In practice, the safety history destroyed the economic rationale for launch.

The principal barriers were:

• Lack of a viable reference-product market.
• High product-liability exposure.
• Physician and payer resistance.
• Regulatory concern over recurrence of severe muscle toxicity.
• Availability of numerous substitute statins.
• Minimal commercial upside compared with litigation and compliance risk.

A generic manufacturer would have faced a product with no active branded market, no meaningful pricing power, and a negative safety association. These factors outweighed any potential benefit from expired or expiring patent rights.

How strong was the cerivastatin patent estate?

Cerivastatin’s patent estate may have provided conventional protection during the product’s launch period, including protection related to the active compound, pharmaceutical compositions, and therapeutic use. Its practical strength must be assessed against the timing of withdrawal.

Patent protection was commercially strong only while the product remained approved, reimbursed, prescribed, and manufacturable. After withdrawal, the estate had little ability to generate revenue. Method-of-use patents could not preserve market share without an approved product, and formulation patents could not overcome the safety-related demand collapse.

The relevant distinction is between formal patent life and usable exclusivity. Cerivastatin lost usable exclusivity when the product lost regulatory and commercial viability.

Did Bayer license or relaunch cerivastatin?

No material post-withdrawal licensing transaction, relaunch, or approved reformulation restored cerivastatin revenue. Bayer did not return Baycol or Lipobay to the major markets after the 2001 withdrawal.

The absence of a licensing or divestiture pathway reflects the same economics that prevented generic entry. A licensee would have inherited regulatory, medical-monitoring, manufacturing, and product-liability risks without a credible revenue base.

What is the long-term financial significance of cerivastatin?

Cerivastatin illustrates how a safety event can convert a growing prescription product into a liability asset. The drug had a functioning commercial model, a large addressable cardiovascular market, and established pharmaceutical manufacturing. Those advantages did not protect its value once the risk-benefit profile became unacceptable.

For Bayer, the economic consequences included:

• Loss of future Baycol and Lipobay sales.
• Product inventory and recall costs.
• Litigation reserves and settlements.
• Legal and regulatory expenses.
• Reduced value of the company’s cardiovascular portfolio.
• Reputational effects across prescriber and payer relationships.

For investors and licensing teams, cerivastatin has no current revenue exposure and no realistic commercial reactivation case. Its remaining relevance is historical, legal, pharmacovigilance-related, and precedent-based.

Key Takeaways

• Cerivastatin sodium was Bayer’s Baycol/Lipobay statin, approved in 1997 and withdrawn globally in 2001.
• The withdrawal followed reports of rhabdomyolysis, kidney failure, and deaths, with particular concern over coadministration with gemfibrozil.
• Peak sales were substantial but vary by source and reporting basis; contemporary estimates range from several hundred million dollars to approximately $1 billion globally.
• There was no commercially meaningful generic launch after withdrawal.
• Cerivastatin has no current U.S. commercial product, biosimilar pathway, or viable relaunch opportunity.
• Litigation and settlement exposure continued for years after revenue ended.
• Patent rights became commercially irrelevant once regulatory approval and market demand collapsed.
• Atorvastatin, simvastatin, pravastatin, and later rosuvastatin captured much of the displaced statin demand.

FAQs

Is cerivastatin sodium still available in the United States?

No. Bayer withdrew Baycol from the U.S. market in August 2001, and cerivastatin has no active U.S. commercial product.

Did cerivastatin have a generic equivalent?

No commercially significant generic equivalent replaced Baycol after the withdrawal. The product’s safety history and the availability of substitute statins eliminated the practical incentive for generic development.

Was cerivastatin more potent than other statins?

Cerivastatin was pharmacologically potent at low doses, but potency did not create a sustainable commercial advantage after serious muscle toxicity and drug-interaction concerns emerged.

Did gemfibrozil cause the cerivastatin safety problem?

Gemfibrozil increased cerivastatin exposure and substantially increased the risk of severe muscle toxicity. Serious adverse events also occurred in patients who were not receiving gemfibrozil.

Does cerivastatin still have investment value?

Cerivastatin has no meaningful operating or licensing value. Its remaining relevance is limited to historical product-liability analysis, pharmacovigilance, regulatory precedent, and research into statin-associated muscle toxicity.

References

1. Bayer AG. (2001-2005). Annual reports and financial statements. Bayer AG.

2. U.S. Food and Drug Administration. (2001, August 8). Baycol and Lipobay withdrawal. U.S. Department of Health and Human Services. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2001). FDA public health advisory: Cerivastatin and rhabdomyolysis. U.S. Department of Health and Human Services. https://www.fda.gov/

4. Staffa, J. A., Chang, J., & Green, L. (2002). Cerivastatin and reports of fatal rhabdomyolysis. New England Journal of Medicine, 346(7), 539-540.

5. Furberg, C. D., & Pitt, B. (2001). Withdrawn: Cerivastatin, an unnecessarily hazardous statin. Current Controlled Trials in Cardiovascular Medicine, 2, 205-206.